Intended for licensed healthcare professionals located in Denmark.
Read the compulsory information here – Denmark abbreviated prescribing information
ICLUSIG
Home
View expert videos
on ICLUSIG
ICLUSIG
resources
Because Tomorrows Matters Today
Blue square
Experts tell the ICLUSIG story

since the initial approval of iclusig in europe in 2013, we have over 10 years of experience in treating patients with cml

Video intro icon
Click on the short videos below to see how far we’ve come and learn why the experts think you should consider switching eligible patients with CML* to ICLUSIG after one 2G TKI...
Watch video
Valentín García-Gutiérrez
Servicio de Hematología
Hospital Universitario Ramón y Cajal (IRYCIS)
Madrid, Spain
Before the discovery of ICLUSIG, treatment failure in CML was devastating for patients1–3
Watch video
Simona Soverini
Institute of Hematology
‘L. & A. Seràgnoli’
University of Bologna
Bologna, Italy
ICLUSIG became the first and remains the only pan-inhibitor of BCR::ABL1 approved for CML in Europe, collectively suppressing all single point mutations (including T315I)4,5
Watch video
Jane Apperley
Centre for Haematology
Hammersmith Hospital
Imperial College London
London, UK
ICLUSIG has been with you since 2013, proudly demonstrating fast, deep and durable responses as seen in the long-term follow-up of the PACE study5,6
Watch video
Jorge Cortes
Georgia Cancer Center
Augusta, GA, USA
Thanks to the recent response-based dosing study, OPTIC, there’s now clear evidence to induce, reduce and maintain ICLUSIG to manage your patients7
Induce response with 45 mg orally, once daily; reduce dose to 15 mg orally, once daily, upon achievement of ≤1% BCR::ABL1; maintain response with 15 mg orally, once daily.
ICLUSIG: COMMITMENT TO BUILDING PATIENTS' FUTURES
Access further resources,
including safety information,
and learn more about ICLUSIG
Click here

*ICLUSIG is indicated in adult patients with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315l mutation. ICLUSIG is also indicated in adult patients with Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315l mutation.

Abbreviations: 2G, second-generation; CML, chronic myeloid leukaemia; CP, chronic phase; ELN, European LeukemiaNet; OPTIC, Optimizing Ponatinib Treatment in CP-CML; PACE, Ponatinib Ph+ ALL and CML Evaluation Phase 2; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia; TKI, tyrosine kinase inhibitor.

References: 1. Leukaemia Care. Living with Leukaemia: 2018 Report. Available at: https://media.leukaemiacare.org.uk/wp-content/uploads/Living-with-Leukaemia-2018-Full-Report-Web-Version.pdf (accessed September 2024); 2. Miller GD, et al. Biologics. 2014;8:243–54; 3. Cortes J, Lang F. J Hematol Oncol. 2021;14:4; 4. O’Hare T, et al. Cancer Cell. 2009;16:401–12; 5. ICLUSIG® (ponatinib). Summary of Product Characteristics. Incyte. 2022; 6. Cortes JE, et al. Blood. 2018;132:393–404; 7. Cortes JE, et al. Blood. 2021;138:2042–50.

Privacy Policy Cookie Policy Terms of Use

Please refer to the product information of your home country for more information.

DK/ICLG/P/24/0010
Date of preparation: September 2024

© 2024, Incyte. All rights reserved.
Marketing authorisation holder: Incyte Biosciences Denmark ApS.
ICLUSIG, the ICLUSIG logo and the Incyte logo are registered trademarks of Incyte.

If you would like to request further medical information, please visit:
www.incyteglobalmedicalinformation.com